Celldex Therapeutics (NASDAQ:CLDX) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX) in a report published on Tuesday morning, Benzinga reports. HC Wainwright currently has a $80.00 price target on the biopharmaceutical company’s stock.

Other equities analysts have also recently issued reports about the stock. Stifel Nicolaus initiated coverage on shares of Celldex Therapeutics in a research note on Tuesday, June 18th. They set a buy rating and a $58.00 price target for the company. Cantor Fitzgerald reissued an overweight rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research note on Tuesday, June 18th. Finally, Wolfe Research started coverage on shares of Celldex Therapeutics in a research note on Tuesday, June 11th. They issued an outperform rating and a $51.00 target price for the company. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of Moderate Buy and a consensus target price of $62.17.

Celldex Therapeutics Stock Down 7.4 %

Shares of CLDX opened at $34.78 on Tuesday. The stock has a market capitalization of $2.29 billion, a P/E ratio of -12.20 and a beta of 1.58. Celldex Therapeutics has a twelve month low of $22.11 and a twelve month high of $53.18. The company has a 50 day moving average of $36.74 and a 200-day moving average of $39.10.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.11. The company had revenue of $0.16 million during the quarter, compared to analysts’ expectations of $1.30 million. Celldex Therapeutics had a negative net margin of 2,385.57% and a negative return on equity of 29.55%. On average, sell-side analysts anticipate that Celldex Therapeutics will post -2.39 earnings per share for the current fiscal year.

Insider Buying and Selling at Celldex Therapeutics

In other Celldex Therapeutics news, SVP Diane C. Young sold 45,000 shares of the firm’s stock in a transaction on Friday, June 7th. The stock was sold at an average price of $35.26, for a total transaction of $1,586,700.00. Following the completion of the sale, the senior vice president now owns 2,115 shares of the company’s stock, valued at approximately $74,574.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Celldex Therapeutics news, SVP Diane C. Young sold 45,000 shares of the firm’s stock in a transaction on Friday, June 7th. The stock was sold at an average price of $35.26, for a total transaction of $1,586,700.00. Following the completion of the sale, the senior vice president now owns 2,115 shares of the company’s stock, valued at approximately $74,574.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Samuel Bates Martin sold 35,000 shares of the firm’s stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $34.05, for a total value of $1,191,750.00. Following the sale, the chief financial officer now directly owns 25,128 shares of the company’s stock, valued at approximately $855,608.40. The disclosure for this sale can be found here. Insiders sold 266,332 shares of company stock valued at $9,155,821 in the last quarter. 3.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Celldex Therapeutics

A number of institutional investors have recently modified their holdings of the business. Wellington Management Group LLP boosted its position in shares of Celldex Therapeutics by 19.2% in the fourth quarter. Wellington Management Group LLP now owns 6,476,561 shares of the biopharmaceutical company’s stock valued at $256,860,000 after acquiring an additional 1,044,728 shares during the period. Vanguard Group Inc. boosted its position in shares of Celldex Therapeutics by 19.8% in the first quarter. Vanguard Group Inc. now owns 3,650,582 shares of the biopharmaceutical company’s stock valued at $153,215,000 after acquiring an additional 604,251 shares during the period. Eventide Asset Management LLC boosted its position in shares of Celldex Therapeutics by 126.9% in the fourth quarter. Eventide Asset Management LLC now owns 3,630,013 shares of the biopharmaceutical company’s stock valued at $143,966,000 after acquiring an additional 2,030,013 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of Celldex Therapeutics by 631.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company’s stock valued at $129,571,000 after acquiring an additional 2,664,915 shares during the period. Finally, Bellevue Group AG boosted its position in shares of Celldex Therapeutics by 15.7% in the first quarter. Bellevue Group AG now owns 2,796,615 shares of the biopharmaceutical company’s stock valued at $117,374,000 after acquiring an additional 380,319 shares during the period.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.